Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
small cell lung cancer
Biotech
Merck, Daiichi repeat early success in small cell lung cancer
Merck and Daiichi reported an objective response rate of 54.8% in the 42 patients who received 12 mg/kg of I-DXd.
Nick Paul Taylor
Sep 9, 2024 10:27am
Merck stops phase 3 TIGIT trial in lung cancer for futility
Aug 8, 2024 7:49am
Daiichi pays Merck $170M to form lung cancer T-cell engager pact
Aug 6, 2024 8:17am
Novartis entrenches into radiopharma with $1B Mariana buy
May 2, 2024 7:00am
Merck inks $680M Harpoon buyout to challenge Amgen
Jan 8, 2024 8:41am
Amgen details ph. 2 tarlatamab data in patients with SCLC
Oct 20, 2023 11:30am
